The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists’ Perspective

At the outset of the coronavirus disease 2019 (COVID-19) pandemic, it was clear that a vaccine would be crucial for global health efforts. The Pfizer and BioNTech teams came together in a race against the virus, working to design, test, manufacture, and distribute a safe and efficacious vaccine in r...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 2023-03, Vol.112 (3), p.640-647
Main Authors: Lewis, Lavinia M, Badkar, Advait V, Cirelli, David, Combs, Rodney, Lerch, Thomas F
Format: Article
Language:English
Subjects:
BNT162 Vaccine
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 Vaccines
Global Health
Humans
Lipid Nanoparticles
mRNA
Pharmaceutical Preparations
RNA, Messenger
Vaccine
Vaccine delivery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:At the outset of the coronavirus disease 2019 (COVID-19) pandemic, it was clear that a vaccine would be crucial for global health efforts. The Pfizer and BioNTech teams came together in a race against the virus, working to design, test, manufacture, and distribute a safe and efficacious vaccine in record time for people around the world. Here, we provide backstory commentary from the pharmaceutical scientist perspective on the challenges and solutions encountered in the development of the Pfizer-BioNTech mRNA COVID-19 vaccine (BNT162b2; b2; Comirnaty®; tozinameran). We discuss the foundational science that led to the decision to use an mRNA-based approach. We also describe key challenges in the identification of an optimal vaccine candidate and testing in clinical trials, the continuous efforts to improve the vaccine formulation in response to changing global health priorities and facilitate vaccine accessibility, and how vast quantities of vaccine doses were manufactured and safely delivered to every corner of the globe, all without compromising quality, science, and safety. The key to successfully delivering a safe and efficacious vaccine within nine months was a result of extraordinary, real-time, parallel effort and across-the-board collaboration between stakeholders on a global scale.
ISSN:0022-3549
1520-6017
DOI:10.1016/j.xphs.2022.09.014